The long-term-oriented basis for investing in BSD Medical is truly compelling:
1) Sound theoretical reasons for expecting precise heating to be very effective for a) tumor ablation and for b) potentiating the long-established therapies of surgery, radiotherapy, and chemotherapy.
2) Many completed and ongoing trials, including Phase 3 trials, proving the efficacy of microwave electrohyperthermia and ablation.
3) The trials have also proved microwave-heating therapy outstandingly safe -- in contrast to the inherent, serious side effects so well-known from surgery, radiotherapy, and chemotherapy – and other less effective new techniques such as radiofrequency heating, ultrasound, and cryoablation.
4) Unlike yet another surgery technique or yet another cancer drug or yet another form of hard radiation, cancer therapy by microwave-induced heating is a “new” and widely-applicable TYPE of cancer therapy (actually has been developed, proven, and used over decades; only “new” regarding wide practice).
5) BSD Medical has developed several highly-advanced products for microwave ablation and electrohyperthermia – they are the acknowledged world leader in this technology.
6) Numerous, new long-term contracts have now been signed/are being signed – worldwide – with major distributers. And, these contracts have specified minimums for far larger amounts than prior contracts (which did not specify minimums).
It is not just BSD Medical espousing microwave heating for cancer therapy. This is now a well-proven therapy, and now recognized well enough for medical distributers around the world to commit to marketing BSD Medical’s products. It is easy to project profitability for the company very soon – IMO, probably before the end of CY 2013. However, the precise timing is difficult. And, for some products in most countries, official approvals/renewals are still pending. But, only a few of these are needed for profitable operation!
My prediction is for a far higher level of analyst coverage; at any time. |
